Detection methods for autologous blood doping

Drug Testing and Analysis

Volumn 4, Issue 11, 2012, Pages 876-881

  Segura, J ^a,b   Monfort, N ^a,b   Ventura, R ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Biological passport; Blood transfusion; Plasticizers

Indexed keywords

BLOOD; PLASTIC CONTAINERS; REINFORCED PLASTICS; SOLVENTS;

'CURRENT; BIOLOGICAL PASSPORT; BLOOD DOPING; BLOOD TRANSFUSION; CONTROL LABORATORY; DETECTION METHODS; DOPING CONTROL; OXYGEN DELIVERY; TOTAL HEMOGLOBINS; WORLD ANTI-DOPING AGENCY;

PLASTICIZERS;

ANKYRIN; BETA ACTIN; DIETHYLHEXYLPHTHALATE; ERYTHROCYTE BAND 4.9 PROTEIN; ERYTHROPOIETIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; MICRORNA; PLASTICIZER; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ATHLETE; BLOOD AUTOTRANSFUSION; BLOOD DOPING; BLOOD STORAGE; DOPING; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE VOLUME; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; MANDATORY TESTING; MEDICAL DEVICE; METABOLITE; MUSCLE EXERCISE; OXIDATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETICULOCYTE; REVIEW; SCREENING; SPORT; T LYMPHOCYTE; URINALYSIS;

EID: 84870247661     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.405     Document Type: Review

References (70)

1. C. Jimenez, R. Ventura, J. Segura Detection in urine of eprafoxiral (RSR 13), a potential doping agent, by a routine screening procedure based on methylation followed by gas chromatography/mass spectrometry. Anal. Chim. Acta 2004, 505, 227.
2. C. Goebel, C. Alma, C. Howe, R. Kazlauskas, G. Trout Methodologies for detection of hemoglobin-based oxygen carriers. J. Chromatogr. Sci. 2005, 43, 39.
3. Y.O. Schumacher, M. Ashenden Doping with artificial oxygen carriers: An update. Sports Med. 2004, 34, 141.
4. C. Reichel, G. Gmeiner Erythropoietin and analogs. Handb. Exp. Pharmacol. 2010, 195, 251.
5. S. Leigh-Smith Blood boosting. Brit. J. Sports Med. 2004, 38, 99.
6. S. Elliott Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Brit. J. Pharmacol. 2008, 154, 529.
7. M. Thevis, A. Thomas, M. Kohler, S. Beuck, W. Schanzer Emerging drugs: Mechanism of action, mass spectrometry and doping control analysis. J. Mass Spectrom. 2009, 44, 442.
8. M. Nelson, M. Ashenden, M. Langshaw, H. Popp Detection of homologous blood transfusion by flow cytometry: A deterrent against blood doping. Haematologica 2002, 87, 881.
9. M. Nelson, H. Popp, K. Sharpe, M. Ashenden Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica 2003, 88, 1284.
10. S.C. Voss, M. Thevis, T. Schinkothe, W. Schanzer Detection of homologous blood transfusion. Int. J. Sports Med. 2007, 28, 633.
11. S. Giraud, N. Robinson, P. Mangin, M. Saugy Scientific and forensic standards for homologous blood transfusion anti-doping analyses. Forensic Sci. Int. 2008, 179, 23.
12. P.A. Arndt, B.M. Kumpel Blood doping in athletes--detection of allogeneic blood transfusions by flow cytofluorometry. Am. J. Hematol. 2008, 83, 657.
13. J. Mallorqui, J. Segura, C. de Bolos, R. Gutierrez-Gallego, J.A. Pascual Recombinant erythropoietin found in seized blood bags from sportsmen. Haematologica 2008, 93, 313.
14. B. Ekblom, A.N. Goldberg, B. Gullbring Response to exercise after blood loss and reinfusion. J. Appl. Physiol. 1972, 33, 175.
15. F.J. Buick, N. Gledhill, A.B. Froese, L. Spriet, C. Meyers Effecto of induced erythrocythemia on aerobic work capacity. J. Appl. Physiol. 1980, 48, 636.
16. M.H. Williams, S. Wesseldine, T. Somma, R. Schuster The effect of induced erhytrocythemia upon 5-mile treadmill run time. Med. Sci. Sports. Exerc. 1981, 13, 169.
17. J.M. Thomson, J.A. Stone, A.D. Ginsburg, P. Hamilton The effects of blood reinfusion during prlonged, heavy exercise. Can. J. Appl. Sport. Sci. 1983, 8, 72.
18. N. Gledhill The influence of altered blood volume and oxygen transport capacity on aerobic performance. Exerc. Sport Sci. Rev. 1985, 13, 75.
19. A.J. Brien, T.L. Simon The effects of red blood cell infusion on 10-km race time. JAMA. 1987, 257(20), 2761.
20. H.G. Klein Blood Transfusion and Athletics - Games People Play. New Engl. J. Med. 1985, 312, 854.
21. M.N. Sawka, M.J. Joyner, D.S. Miles, R.J. Robertson, L.L. Spriet, A.J. Young ACSM Position Stand: The Use of Blood Doping as an Ergogenic Aid. Med. Sci. Sports. Exerc. 1996, 28, 127.
22. Anonymous. A statement from the Medical Commission of International Olympic Committee. Brit. J. Sports Med. 1988, 23, 60.
23. B. Berglund, P. Hemmingsson, G. Birgegard Detection of autologous blood transfusions in cross-country skiers. Int. J. Sports. Med. 1987, 8, 66.
24. R. Damsgaard, T. Munch, J. Morkeberg, S.P. Mortensen, J. Gonzalez-Alonso Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies. Haematologica 2006, 91, 1006.
25. P. Sallet, E. Brunet-Guedj, R. Mornex, G. Baverel Study of a new indirect method based on absolute norms of variation to detect autologous blood transfusion. Int. J. Hematol. 2008, 88, 362.
26. V. Pialoux, R. Mounier, J.V. Brugniaux Hemoglobin and hematocrit are not such good candidates to detect autologous blood doping. Int. J. Hematol. 2009, 89, 714.
27. J. Morkeberg, B. Belhage, A.B. Rasmussen, R. Damsgaard, M. Ashenden, M.H. Dziegiel Changes in red blood cell volume, plasma volume, and total blood volume after autologous blood collections. Transfusion 2008, 48, 1524.
28. J. Morkeberg, K. Sharpe, B. Belhage, R. Damsgaard, W. Schmidt, N. Prommer, et al. Detecting autologous blood transfusions: A comparison of three passport approaches and four blood markers. Scand. J. Med. Sci. Sports 2011, 21, 235.
29. J. Morkeberg, B. Belhage, M. Ashenden, A. Borno, K. Sharpe, M.H. Dziegiel, et al. Screening for autologous blood transfusions. Int. J. Sports Med. 2009, 30, 285.
30. T. Pottgiesser, M. Umhau, C. Ahlgrim, S. Ruthardt, K. Roecker, Y.O. Schumacher Hb mass measurement suitable to screen for illicit autologous blood transfusions. Med. Sci. Sports Exerc. 2007, 39, 1748.
31. T. Pottgiesser, W. Specker, M. Umhau, K. Roecker, Y.O. Schumacher Post-transfusion stability of haemoglobin mass. Vox Sang. 2009, 96, 119.
32. World Anti-Doping Agency. Athlete Biological Passport Operating Guidelines and Compilation of Required Elements, Version 2.0. 2010.
33. T. Pottgiesser, P.E. Sottas, T. Echteler, N. Robinson, M. Umhau, Y.O. Schumacher Detection of autologous blood doping with adaptively evaluated biomarkers of doping: A longitudinal blinded study. Transfusion 2011, 51, 1707.
34. V. Diaz, G. Lombardi, C. Ricci, R.A. Jacobs, Z. Montalvo, C. Lunby, et al. Reticulocyte and haemoglobin profiles in elite triathletes over four consecutive seasons. Int. J. Lab. Haemtol. 2011, 33, 638.
35. World Anti-Doping Agency. WADA Technical Document TD2010BAR, Version1.0. 2010.
36. N. Monfort, R. Ventura, A. Latorre, V. Belalcazar, M. Lopez, J. Segura Urinary di-(2-ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: A comparison study with patients receiving blood transfusion. Transfusion 2009, 50, 145.
37. E. Solymos, S. Guddat, H. Geyer, U. Flenker, A. Thomas, J. Segura, et al. Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. Anal. Bioanal. Chem. 2011, 401, 517.
38. N. Monfort, R. Ventura, P. Platen, T. Hinrichs, K. Brixius, W. Schanzer, et al. Plasticizers excreted in urine, indication of autologous blood transfusion in sports. Transfusion 2011. DOI: 10.1111/j.1537-2995.2011.03331.x
39. K. Chou, R.O. Wright Phthalates in food and medical devices. J. Med. Toxicol. 2006, 2, 126.
40. FDA, Public Health Notification [monograph on the Internet] Safety assessment of di(2-ethylhexyl)phthalate (DEHP) released from polyvinyl chloride (PVC) medical devices. US Food and Drug Administration, Center of Devices and Radiological Health, Rockville, MD. [updated 2001; cited 2008 Nov 06]. Available at: www.fda.gov/cdrh/ost/dehp-pvc.pdf
41. European Commission Health & Consumer Protection DG Brussels. The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk. European Commission [updated 2008; cited 2008 Nov 06]. Available at: http://ec.europa.eu/health/ph_risk/risk_en.htm
42. J. Sampson, D. de Korte DEHP-plasticised PVC: Relevance to blood services. Transfusion Med. 2001, 21, 73.
43. L.E. Gray, J. Ostby, J. Furr, M. Price, D.N.R. Veeramachaneni, L. Parks Perinatal exposure to the phthalates DEHP, BBP and DINP, but not DEP, DMP or DOTP alters sexual differentiation of the male rat. Toxicol. Sci. 2000, 5, 350.
44. R.W. Moore, T.A. Rudy, T.M. Lin, K. Ko, R.E. Peterson Abnormalities of sexual development in male rats with in utero and lactational exposure to the androgenic plasticizer di(2-ethylhexyl) phthalate. Environ. Health Persp. 2001, 109, 229.
45. European Commission Scientific Committee on Medicinal Products and Medical Devices (SCMPMD) (2002) Opinion on Medical Devices Containing DEHP Plasticised PVC; Neonates and Other Groups Possibly at Risk from DEHP Toxicity. Available at: http://ec.europa.eu/health/ph_risk/committees/scmp/documents/out43_en.pdf [15 July 2010].
46. European Commission. EC2008, bis(2-ethylhexyl) phthalate (DEHP), European Union Summary Risk Assessment Report, 2008. [updated 2008; cited 2011 Aug]. Available at: http://www.dehpfacts.com/upload/documents/webpage/DEHP%20RA%20report%20summary.pdf
47. A.L. Andrady, M.A. Neal Applications and societal benefits of plastics. Philos. Trans. R. Soc. 2009, 364, 1977.
48. K. Clark, I. Cousins, D. MacKay Assessment of critical exposure pathways. Handb. Environ. Chem. 2003, 3, 227.
49. M.E. Meek, P.K. Chan Bis(2-ethylhexyl)phthalate: evaluation of risks to health from environmental exposure in Canada. J. Environ. Sci. Health 1994, 12, 179.
50. M.A. Kamrin Phthalate risks, phthalate regulation, and public health: A review. J. Toxicol. Environ. Health 2009, 12, 157.
51. M. Wormuth, M. Scheringer, M. Vollenweider, K. Hungerbuhler What are the sources of exposure to eight frequently used phthalic acid esters in Europeans? Risk Anal. 2006, 26, 803.
52. A.M. Calafat, L.L. Needham, M.J. Silva, G. Lambert Exposure to di-(2-ethylhexyl) phthalate among premature neonates in a neonatal intensive care unit. Pediatrics 2004, 113, 429.
53. H.M. Koch, H.M. Bolt, J. Angerer Di(2-ethylhexyl) phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium labelled DEHP. Arch. Toxicol. 2004, 78, 123.
54. R. Preuss, H.M. Koch, J. Angerer Biological monitoring of the five major metabolites of di-(2-ethylhexyl)phthalate (DEHP) in human urine using column switching liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2005, 816, 269.
55. H.M. Koch, R. Preuss, J. Angerer Di(2-ethylhexyl)phthalate (DEHP): Human metabolism and internal exposure an update and latest results. Int. J. Androl. 2006, 29, 155.
56. M.J. Silva, E. Samandar, Jr. J.L. Preau, L.L. Needham, A.M. Calafat Urinary oxidative metabolites of di(2-ethylhexyl) phthalate in humans. Toxicology 2006, 219, 22.
57. K. Kato, M.J. Silva, J.A. Reidy, D. Hurtz, N.A. Malek, L.L. Needham, et al. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ. Health Perspect. 2004, 112, 327.
58. H. Fromme, G. Bolte, H.M. Koch, J. Angerer, S. Boehmer, H. Drexler, et al. Occurrence and daily variation of phthalate metabolites in the urine of an adult population. Int. J. Hyg. Environ. Health 2007, 210, 21.
59. J.L. Preau, L.Y. Wong, M.J. Silva, L.L. Needham, A.M. Calafat Variability over one week in the urinary concentrations of metabolites of diethyl phthalate and di(2-ethylhexyl)phthalate among 8 adults: An observational study. Environ. Health Perspect. 2010, 118, 1748.
60. J. Simmchen, R. Ventura, J. Segura Progress in the removal of di-[2-ethylhexyl]-phthalate (DEHP) as the plasticizer in blood bags. Transf. Med. Rev. DOI: 10.1016/j.tmrv.2011.06.001
61. G. Liumbruno, G.M. D'Amici, G. Grazzini, L. Zolla Transfusion medicine in the era of proteomics. J. Proteomics 2008, 71, 34.
62. A. D'Alessandro, G. Liumbruno, G. Grazzini, L. Zolla Red blood cell storage lesion: The story so far. Blood Transfus. 2010, 8, 82.
63. K. Pavenski, E. Saidenberg, M. Lavoie, M. Tokessy, D.R. Branch Red blood cell storage lesions and related transfusion issues: a canadian blood services research and development symposium. Transfus. Med. Rev. 2011, DOI: 10.1016/j.tmrv.2011.07.003
64. G.M. D'Amici, S. Rinalducci, L. Zolla Proteomic analysis of RBC membrane protein degradation during blood storage. J. Proteome Res. 2007, 6, 3242.
65. Z. Nikolovski, Z.C. De La Torre, C. Chiva, E. Borras, D. Andreu, R. Ventura, et al. Insight into erythrocyte membrane proteome changes after blood storage. 29th Cologne Workshop on Dope Analysis, February 2011.
66. M. Kannan, C. Atreya Differential profiling of human red blood cells during storage for 52 selected microRNAs. Transfusion 2010, 50, 1581.
67. C. Reichel OMICS-strategies and methods in the fight against doping. Forensic Sci. Int. 2011, DOI: 10.1016/j.forsciint.2011.07.031.
68. T.L. Steck The organization of proteins in the human red blood cell membrane. J. Cell. Biol. 1974, 62, 1.
69. T. Pottgiesser, Y.O. Schumacher, H. Funke, K. Rennert, M.W. Baumstark, K. Neunuebel, et al. Gene expression in the detection of autologous blood transfusion in sports-a pilot study. Vox Sang. 2009, 96, 333.
70. World Anti-doping Agency (WADA). Montreal, Canada. The 2011 Prohibited List. WADA.